Quantum Computing has slid less than many peers this year, but tiny revenue, mounting losses and heavy dilution raise big questions about its ability to challenge D‐Wave. Is the outperformance real momentum—or a mirage?
Analysts are overwhelmingly bullish ahead of Q4, citing the earnings release, GTC and heavy institutional buying as catalysts that could fuel 100–200% upside.
Landing in the MSCI World Index validates AST SpaceMobile, Coherent and FTAI Aviation — and will force passive funds to buy by Feb. 27. These hard‐tech winners span satellites that talk to phones, AI optical infrastructure, and jet‐engine power solutions.
A 27% pullback tests sentiment, but Palantir has only penetrated ~2–3% of a rapidly expanding TAM — high margins and AI-driven demand leave the long-term upside intact.
Ciena and Lumentum are powering a massive AI data‐center buildout — and their earnings and orders show the boom is real. After explosive gains, patient investors may find better entry points on pullbacks rather than chasing immediate momentum.
What looked like disruption has become a buying opportunity: AI-driven agent traffic is accelerating revenue and reigniting growth. Analysts are boosting targets and eyeing a run toward fresh all-time highs.
AI fears sparked an emotional sell-off that left best-in-class SaaS names deeply oversold. Here are four leaders — Salesforce, Monday.com, Workday and ServiceNow — that institutions are buying and that look primed to rebound.
Renewed subscriber momentum, bullish technicals and analyst/institutional support — plus a nearly 6% dividend — put Verizon on track for a potential breakout and outsized total returns. The payoff hinges on disciplined network investment and consistent execution.
Shield your portfolio with ETFs that combine low-volatility stocks, long-dated Treasurys and option-based protection to limit downside risk. These picks aim to preserve capital and provide steady income without fully missing out on market upside.
Global orders and a certified propulsion partner validate Vertical’s progress, but looming dilution and a delayed transition flight have sent the stock tumbling. It’s a high-risk bet where certification news could flip sentiment overnight.
Blowout guidance sent Eli Lilly soaring, then Hims’ low‐cost oral GLP‐1 move wiped out much of the gain. Analysts still see double‐digit upside as Lilly readies orforglipron for launch.
Ugly Q2 results hide a funded transformation: a $3.6 billion credit facility and a Microsoft-backed AI contract largely finance IREN’s shift to GPU-powered data centers. Execution on power-rich campuses and rapid GPU deployment will decide whether the stock earns a re-rating.
